


EFFICACY AND SAFETY OF SOTROVIMAB: RESULTS OF A RETROSPECTIVE OBSERVATIONAL STUDY IN A FRENCH HOSPITAL

Covid-19 results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a monoclonal antibody that was designed to prevent progression of Covid-19 in high-risk patients early in the course of disease.

Aim of the study : To assess the **efficacy** and **safety** of SOTROVIMAB for adults infected with Covid-19 in a 400-bed French hospital.



Monocentric retrospective observational study



from January to March 2022



36 adult patients with a **positive result on rt-PCR or antigen SARS-CoV-2 test** and **Covid-19 symptoms within the previous 5 days** received **SOTROVIMAB**



Mean age 83 ± 9 y with 80% patients ≥ 75 y
BMI 25.3 ± 5 ; sex ratio 0.3 (27F ; 9M)

83% patients (30/36) in nursing home





Risk factors for Covid-19 progression	No.
Age ≥ 80 yr	25
Cancer	12
Diabetes for which medication was warranted	8
Obesity: BMI >30	7
Chronic kidney disease	8
Congestive heart failure: \geq NYHA class II	9
Chronic obstructive pulmonary disease / asthma	5

Method of diagnosis	No.
RT-PCR test	31
Antigen test	5


No. of concurrent risk factors for Covid-19 progression

■ 1 risk factor ■ 2 risk factors ■ ≥ 3 risk factors




18 patients (50%) already infected with SARS-CoV-2 virus

30 patients (83%) with a complete schema of Covid-19 vaccine



Efficacy outcomes	No.
Admission to hospital for any cause in patients in nursing home	0/30
Admission to ICU for any cause in hospitalized patients	0/6
Severe or critical progression	
Low-flow oxygenation	3
Death from any cause	2
Death related to Covid-19	1
Associated therapies	
Corticosteroids	3
Anticoagulant	5
Antibiotics	4
Adverse events	
Infusion-related reaction	1
Serious adverse event	0



30 vaccinated patients

1 disease progression leading to low flow oxygenation

1 death related to Covid-19



6 unvaccinated patients

2 disease progression leading to low flow oxygenation

1 death from any cause

Sotrovimab **reduce the risk of disease progression** to hospitalisation or death among patients with mild-to-moderate Covid-19. This seems to be legit in our study, as does the **safety**, especially for elderly patients. Also, the effectiveness of this antibody against disease progression appears to be **better for vaccinated patients**.

